Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : L-Alfa-Glu-Afc
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase IV
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Prophylactic Minimally Invasive Surfactant Evaluation
Details : Poractant Alfa is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Respiratory Distress Syndrome, Newborn.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 23, 2023
Lead Product(s) : L-Alfa-Glu-Afc
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase IV
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : L-Alfa-Glu-Afc
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Curosurf (Poractant Alfa) is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Respiratory Distress Syndrome.
Product Name : Curosurf
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 06, 2020
Lead Product(s) : L-Alfa-Glu-Afc
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : L-Alfa-Glu-Afc
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Cold Heart Study: A Randomized Pilot Trial of Surfactant Therapy
Details : Poractant Alfa is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Heart Defects, Congenital.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 29, 2019
Lead Product(s) : L-Alfa-Glu-Afc
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : L-Alfa-Glu-Afc
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Curosurf (Poractant Alfa) is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Respiratory Distress Syndrome, Newborn.
Product Name : Curosurf
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 01, 2017
Lead Product(s) : L-Alfa-Glu-Afc
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : L-Alfa-Glu-Afc
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Curosurf (Poractant Alfa) is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Respiratory Distress Syndrome.
Product Name : Curosurf
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 13, 2016
Lead Product(s) : L-Alfa-Glu-Afc
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable